Baxalta's corporate venturing vehicle co-led a round that will support the cancer immunotherapy developer as it looks to advance a leukaemia candidate into clinical testing.
Netherland-based cancer immunotherapy developer Gadeta closed a €7m ($7.9) series A round yesterday co-led by Baxalta Ventures, the corporate venturing unit of pharmaceutical company Baxalta, and venture capital firm Medicxi Ventures.
Company founders and management also participated in the round, as did Utrecht Holdings, the knowledge transfer office of Utrecht University and University Medical Center Utrecht.
Founded in 2015, Gadeta is working on cancer immunotherapies based on a technology platform that creates optimised gamma delta T-cell receptors with enhanced anti-cancer…
